Latest News and Press Releases

AGOURA HILLS, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC) announced today a presentation at AACR-2021 (American Association...

AGOURA HILLS, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC) (f/k/a Mateon Therapeutics, Inc.) announced today that the Chopra...

AGOURA HILLS, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC) (f/k/a Mateon Therapeutics, Inc.) announced today that the Financial...

AGOURA HILLS, California, March 15, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the regulatory approval from the Ministry of Food and Drug Safety of Korea for the...

PART 1 AND 2 SENTINEL PATIENTS COMPLETED TREATMENT THE FIRST COHORT OF 18 PART 1 PATIENTS COMPLETED TREATMENT. AGOURA HILLS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics,...

AGOURA HILLS, California, March 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...

AGOURA HILLS, California, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...

AGOURA HILLS, California, Feb. 16, 2021 (GLOBE NEWSWIRE) --  Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...

AGOURA HILLS, California, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases,...

AGOURA HILLS, California, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases,...